Abstract:OBJECTIVE:To investigate the apoptosis and Fas (CD95) expression of T lymphocytes from the peripheral blood and peritoneal fluid of the patients with ovarian cancer and their relationship with CA125. METHODS:Apoptosis and Fas expression of peritoneal fluid and peripheral blood T lymphocytes were assessed by flow cytometry. Peripheral blood samples were obtained from the following objects respectively: patients with stage III - IV ovarian cancer (n = 18) before and after treatment, patients with stage I - II ovarian cancer (n = 15), patients with benign ovarian tumor (n = 18), patients with Krukenberg tumor (n = 6) and normal control (n = 20). Peritoneal fluids were obtained from all the patients with ovarian cancer, Krukenberg tumor and ten patients with benign ovarian tumor. Level of serum CA125 of the patients with ovarian cancer was assessed. RESULTS:In the patients with stage III - IV ovarian cancer, the apoptosis level of the peripheral blood T lymphocytes was 5.55 (3.57 - 9.62)%, significantly higher than those from the patients with stage I - II ovarian cancer, patients with benign ovarian tumor, controls (P < 0.008 in all instances) and the patients with stage III - IV ovarian cancer after treatment (P < 0.05). The intensity of Fas expression of the peripheral blood T lymphocytes from the patients with stage III - IV ovarian cancer was 51 +/- 10, significantly higher than that from controls (P < 0.05). In peritoneal fluid, the apoptosis rates of T lymphocytes, positive rate and intensity of Fas expression on T lymphocytes from patients with stage I - II and stage III - IV ovarian cancer were 17.41 (7.06 - 24.56)%, (57 +/- 16)%, (55 +/- 11)% and 34.06 (17.03 - 44.65)%, (66 +/- 12)%, (70 +/- 24)%, respectively, increased significantly compared with those from patients with benign ovarian tumor, which were 0.78 (0.67 - 1.44)%, (37 +/- 6)%, 43 +/- 6, respectively (P < 0.01 in all instances). The apoptosis level and positive rate of Fas expression on peritoneal fluid T lymphocytes from patients with stage III - IV ovarian cancer were significantly higher than those from patients with Krukenberg tumor (P < 0.01). There was a positive correlation between the serum CA125 level and the apoptosis level of peritoneal fluid T cell in the patients with stage I - II ovarian cancer (r = 0.77, P = 0.009). For ovarian cancer, the apoptosis level of peritoneal fluid T lymphocytes from patients with the serum CA125 > 500 KU/L was higher than that from the patients with the serum CA125 < or = 500 KU/L (P = 0.009). CONCLUSIONS:(1) Extraordinarily increased apoptosis of T cells may play an important role in the development of systemic and celiac immunodeficiency in the patients with ovarian cancer. In contrast with the patients with Krukenberg tumor, the patients with advanced ovarian cancer hare higher percentage of apoptotic peritoneal fluid T lymphocytes, which shows the particularity of local immunity defect. (2) For the patients with ovarian cancer, efficient treatment can decrease the percentage of apoptotic peripheral blood T lymphocytes. (3) The increased positive rate and intensity of Fas expression on peritoneal fluid T lymphocytes stressed the significance of Fas interference in the treatment of ovarian cancer. (4) Level of serum CA125 can reflect the celiac immunity defection in patients with ovarian cancer.

Comparison of serum Vascular Cell Adhesion Molecule (VCAM) level among epithelial ovarian cancer patients and healthy women

Expression and clinical significance of P16, P15,and VEGF proteins in primary epithelial ovarian carcinoma

[Significance of Concentration of Serum Soluble Vascular Cell Adhesion Molecule-1 in Epithelial Ovarian Carcinoma].

[Expressions of VEGF/VEGFRs and Activation of STATs in Ovarian Carcinoma].

Study of Apoptosis and Fas Expression of Peritoneal Fluid and Peripheral Blood T Lymphocytes in Patients with Epithelial Ovarian Cancer and Their Relationship with CA125

VEGF, VEGFRs Expressions and Activated STATs in Ovarian Epithelial Carcinoma

Clinical Significance Of Ngal And Mmp-9 Protein Expression In Epithelial Ovarian Cancers

Serum amyloid a, a potential biomarker both in serum and tissue, correlates with ovarian cancer progression

Correlation of Molecular Tumor Markers CA125, HE4, and CEA with the Development and Progression of Epithelial Ovarian Cancer

Determining the Diagnostic Strength of Serum Tumor Markers in Epithelial Ovarian Cancer in Women from Lahore, Pakistan

Preoperative plasma fibrinogen, platelet count and prognosis in epithelial ovarian cancer.

Serum Levels of Vascular Endothelial Growth Factor in Epithelial Ovarian Neoplasm

Prevelance of Ovarian Cancer and its Correlation with Age in Pakistan

Evaluation of Serum Cancer Antigen (CA)-125 Levels as a Biomarker for Ovarian Lesions: Correlation With Histopathological Diagnosis and Clinical Outcomes

Comparison of vascular endothelial growth factor C expression between primary and metastatic sites of ovarian cancer

Evaluation of Serum s EGFR in Ovarian Tumors, its Comparison with Serum CA125, HE4 and Correlation with Histopathological Types

Combined evaluation of some tumor associated antigens in the monitoring of integrated surgical and chemotherapeutic treatment of epithelial ovarian cancer

Understanding the Correlation between Metabolic Regulator SIRT1 and Exosomes with CA-125 in Ovarian Cancer: A Clinicopathological Study

A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer

A CLINICOPATHOLOGICAL STUDY OF OVARIAN TUMORS AND ITS CORRELATION WITH PREOPERATIVE SERUM CA125 LEVELS

Differential Expression of HIF1A, EPAS1, and VEGF Genes in Benign and Malignant Ovarian Neoplasia